Logo Image
News|Podcasts|February 26, 2026

Pharmaceutical Executive Daily: Alkermes' CEO Succession Plan

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.

Alkermes has revealed its CEO succession plan after longtime chief executive Richard Pops announced his retirement. Pops has led the company for decades, overseeing its transition into a diversified neuroscience-focused biopharma. The leadership transition marks a pivotal moment as Alkermes continues advancing its commercial portfolio and pipeline strategy.

In broader leadership news, Sarepta Therapeutics’ CEO has announced plans to retire, while Rivus Pharmaceuticals has appointed a new chief executive to guide its next stage of growth. The moves reflect ongoing executive reshuffling across the biotech sector as companies adapt to shifting capital markets, regulatory dynamics, and pipeline priorities.

Finally, Boehringer Ingelheim has acquired an exclusive license to a preclinical small-molecule program from Sitryx Therapeutics. The agreement strengthens Boehringer’s research portfolio and underscores continued investment in early-stage assets through external innovation partnerships.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Read more
Pharmaceutical executive daily
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.
Read more